Class 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17
UKClass 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17
Recalling Firm: Sandoz Limited
Reason for Recall / Hazard
Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information....
Product Description & Identification
Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information.
Affected Products
Class 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17
Additional Source Details
| Field | Value |
|---|---|
| Guid | tag:www.gov.uk,2005:/drug-device-alerts/class-4-medicines-defect-notification-sandoz-limited-apixaban-2-dot-5mg-and-5mg-tablets-el-26-a-slash-17 |
| Link | https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-sandoz-limited-apixaban-2-dot-5mg-and-5mg-tablets-el-26-a-slash-17 |
| Pub Date | 2026-03-26T14:01:58+00:00 |
| Extracted category | drugs |
Check Other Products In Your Household
Free ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmSandoz Limited
- Risk LevelMedicines Recall
- DistributionUnited Kingdom
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: Sandoz Limited - Class 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17 Check if your household is affected: https://therecallfile.com/recalls/class-4-medicines-defect-notification-sandoz-limited-apixaban-2-5mg-an/UK-MHRA-class-4-medicines-defect-notification-sandoz-limited-apixaban-2-dot-5mg-and-5mg-tablets-el-26-a-slash-17
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Related Recalls
UKClass 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged r...
AustraliaGLP-1 RAs and rare, but severe, eye disorders
GLP-1 RAs and rare, but severe, eye disorders
Product warnings across the GLP-1 RA class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder....
UKClass 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect t...